Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Stoke Therapeutics will host a webcast and conference call on October 29, 2026, at 4:30 p.m. to discuss third-quarter business and financial updates. The event targets analysts and investors seeking insights into the company's current performance. Stoke continues to develop zorevunersen as a potential disease-modifying treatment for Dravet syndrome. Management will address strategic progress during the scheduled session.

Market Sentiment Analysis

POSITIVE FACTORS

  • Stoke Therapeutics is focused on RNA medicine.
  • The company is developing zorevunersen for Dravet syndrome.
  • Management is engaging with analysts and investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
6.8%
average across 5 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
zorevunersen
Phase 3 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m.

Frequently Asked Questions

When is the Stoke Therapeutics conference call?

The conference call is scheduled for October 29, 2026, at 4:30 p.m.

What is zorevunersen developed for?

Zorevunersen is being developed for Dravet syndrome.

What type of company is Stoke Therapeutics?

Stoke Therapeutics focuses on RNA medicine and protein expression.

Who will host the conference call?

Management of Stoke Therapeutics will host the call.

ShareAdd on Google
Tags: STOK Stoke Therapeutics zorevunersen Dravet syndrome Q3 2026 biotechnology
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$354M liquidity · $19M/mo burn
~17 mo
Low dilution risk
Lead asset
zorevunersenPhase 3
Dravet Syndrome →

Catalyst track record

+11%
best trade around STOK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for STOK.

See every catalyst's timing & PoA →